Literature DB >> 13130102

Surrogate end points for prostate cancer: what is prostate-specific antigen telling us?

Howard M Sandler, Michelle L DeSilvio.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 13130102     DOI： 10.1093/jnci/djg071

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  2 in total

1.  Adaptive seamless design for an efficacy trial of replication-competent adenovirus-mediated suicide gene therapy and radiation in newly-diagnosed prostate cancer (ReCAP Trial).

Authors:  Mei Lu; Svend O Freytag; Hans Stricker; Jae Ho Kim; Kenneth Barton; Benjamin Movsas
Journal:  Contemp Clin Trials       Date:  2011-02-12       Impact factor: 2.226

2.  Preliminary Case Series of Artemisinin for Prostate Cancer in a Naturopathic Practice.

Authors:  Eric Yarnell
Journal:  J Restor Med       Date:  2015-12-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.